Clinical trials with CAMPATH-I and other monoclonal antibodies.
Hale
G
G
Department of Pathology, University of Cambridge, U.K.
Phillips
J M
JM
D000074323:Alemtuzumab; D000818:Animals; D000888:Antibodies, Anti-Idiotypic / Q000096:biosynthesis; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm / Q000009:adverse effects / Q000627:therapeutic use*; D000961:Antilymphocyte Serum / Q000627:therapeutic use; D015415:Biomarkers; D002986:Clinical Trials as Topic; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use; D051379:Mice; D009103:Multiple Sclerosis / Q000628:therapy; D051381:Rats; D014657:Vasculitis / Q000628:therapy
D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D000961:Antilymphocyte Serum; D015415:Biomarkers; D007074:Immunoglobulin G; D000074323:Alemtuzumab